Yevgeniy Khariton
Overview
Explore the profile of Yevgeniy Khariton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassif M, Nguyen D, Spertus J, Gosch K, Tang F, Windsor S, et al.
J Card Fail
. 2023 May;
29(9):1324-1328.
PMID: 37230315
Background: Remote monitoring of pulmonary artery (PA) pressures and serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements guide heart failure (HF) treatment, but their association has yet to be described. Methods...
2.
Khariton Y, Hassan O, Hernandez-Montfort J
Curr Opin Cardiol
. 2023 Jan;
38(2):108-115.
PMID: 36718620
Purpose Of Review: The following review is intended to provide a summary of contemporary cardiogenic shock (CS) profiling and diagnostic strategies, including biomarker and hemodynamic-based (invasive and noninvasive) monitoring, discuss...
3.
Nassif M, Windsor S, Borlaug B, Kitzman D, Shah S, Tang F, et al.
Nat Med
. 2021 Oct;
27(11):1954-1960.
PMID: 34711976
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium...
4.
Nassif M, Spertus J, Tang F, Windsor S, Jones P, Thomas M, et al.
Circ Heart Fail
. 2021 Oct;
14(11):e008446.
PMID: 34696602
No abstract available.
5.
Thomas M, Khariton Y, Fonarow G, Arnold S, Hill L, Nassif M, et al.
ESC Heart Fail
. 2021 May;
8(4):2670-2678.
PMID: 33932120
Aims: Improving the health status (symptoms, function, and quality of life) of patients with heart failure with reduced ejection fraction (HFrEF) is a primary treatment goal. Angiotensin receptor neprilysin inhibitors...
6.
Nassif M, Windsor S, Tang F, Husain M, Inzucchi S, McGuire D, et al.
Diabetes Obes Metab
. 2021 Feb;
23(6):1426-1430.
PMID: 33606921
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular death or worsening heart failure (HF), and improve symptom burden, physical function and quality of life in...
7.
Khariton Y, Fonarow G, Hellkamp A, Thomas L, Nassif M, Butler J, et al.
ESC Heart Fail
. 2020 Nov;
8(1):710-713.
PMID: 33170559
Aims: The aim of our study was to investigate heterogeneity of health status treatment response of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF). Methods And Results:...
8.
Hejjaji V, Scholes A, Kennedy K, Sperry B, Khariton Y, Dean E, et al.
Circ Cardiovasc Qual Outcomes
. 2020 Sep;
13(11):e006168.
PMID: 32981336
No abstract available.
9.
Qarajeh R, Singh A, Khariton Y, Rafie N, Baweja P
Cureus
. 2020 May;
12(4):e7605.
PMID: 32399339
Myocardial infarction with no obstructive coronary atherosclerosis (MINOCA) is a distinct clinical syndrome characterized by evidence of myocardial infarction with normal or near-normal coronary arteries on angiography (stenosis severity <...
10.
Nassif M, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi S, et al.
Circulation
. 2019 Sep;
140(18):1463-1476.
PMID: 31524498
Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and...